Results 231 to 240 of about 743,371 (240)

Investment in Cancer Control and Research: A Sure Bet

Ca-A Cancer Journal for Clinicians, 2006
Carolyn D Runowicz
exaly  

Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors

ACS Medicinal Chemistry Letters, 2013
Jennifer Mertz, Christopher G Nasveschuk, Michael C Hewitt   +2 more
exaly  

Current status in the discovery of dual BET/HDAC inhibitors

Bioorganic and Medicinal Chemistry Letters, 2021
exaly  

BET Inhibitors as Anticancer Agents: A Patent Review

Recent Patents on Anti-Cancer Drug Discovery, 2017
Gildon Choi
exaly  

Naphthyridines as Novel BET Family Bromodomain Inhibitors

ChemMedChem, 2014
Paul Bamborough, Chun-Wa Chung, Olivier Mirguet   +2 more
exaly  

Disrupting Acetyl-lysine Interactions: Recent Advance in the Development of BET Inhibitors

Current Drug Targets, 2018
Nan Zhang
exaly  

Development of methyl isoxazoleazepines as inhibitors of BET

Bioorganic and Medicinal Chemistry Letters, 2015
Jennifer Mertz, Michael C Hewitt, Alexandre Coté   +2 more
exaly  

Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors

Proceedings of the National Academy of Sciences of the United States of America, 2019
Pei Hui, Eliana Bignotti, Salvatore Lopez   +2 more
exaly  

Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML)

Expert Opinion on Investigational Drugs, 2017
exaly  

A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors

Ca-A Cancer Journal for Clinicians
Jennifer Litton, Nicolas Sayegh, Chadi Hage Chehade   +2 more
exaly